Back to Search Start Over

Post–COVID-19 Conditions Among Children 90 Days After SARS-CoV-2 Infection

Authors :
Pediatría
Pediatria
Funk, Anna L.
Kuppermann, Nathan
Florin, Todd A.
Tancredi, Daniel J.
Xie, Jianling
Kim, Kelly
Finkelstein, Yaron
Neuman, Mark I.
Salvadori, Marina I.
Yock-Corrales, Adriana
Breslin, Kristen A.
Ambroggio, Lilliam
Chaudhari, Pradip P.
Bergmann, Kelly R.
Gardiner, Michael A.
Nebhrajani, Jasmine R.
Campos, Carmen
Ahmad, Fahd A.
Sartori, Laura F.
Navanandan, Nidhya
Kannikeswaran, Nirupama
Caperell, Kerry
Morris, Claudia R.
Mintegi Raso, Santiago
Gangoiti, Iker
Sabhaney, Vikram J.
Plint, Amy C.
Klassen, Terry P.
Avva, Usha R.
Shah, Nipam P.
Dixon, Andrew C.
Lunoe, Maren M.
Becker, Sarah M.
Rogers, Alexander J.
Pavlicich, Viviana
Dalziel, Stuart R.
Payne, Daniel C.
Malley, Richard
Borland, Meredith L.
Morrison, Andrea K.
Bhatt, Maala
Rino, Pedro B.
Beneyto Ferre, Isabel
Eckerle, Michelle
Kam, April J.
Chong, Shu-Ling
Palumbo, Laura
Kwok, Maria Y.
Cherry, Jonathan C.
Poonai, Naveen
Waseem, MD; Norma-Jean Simon, MPH
Waseem, Muhammad
Simon, Norma-Jean
Freedman, Stephen B.
Pediatric Emergency Research Network–COVID-19 Study Team
Pediatría
Pediatria
Funk, Anna L.
Kuppermann, Nathan
Florin, Todd A.
Tancredi, Daniel J.
Xie, Jianling
Kim, Kelly
Finkelstein, Yaron
Neuman, Mark I.
Salvadori, Marina I.
Yock-Corrales, Adriana
Breslin, Kristen A.
Ambroggio, Lilliam
Chaudhari, Pradip P.
Bergmann, Kelly R.
Gardiner, Michael A.
Nebhrajani, Jasmine R.
Campos, Carmen
Ahmad, Fahd A.
Sartori, Laura F.
Navanandan, Nidhya
Kannikeswaran, Nirupama
Caperell, Kerry
Morris, Claudia R.
Mintegi Raso, Santiago
Gangoiti, Iker
Sabhaney, Vikram J.
Plint, Amy C.
Klassen, Terry P.
Avva, Usha R.
Shah, Nipam P.
Dixon, Andrew C.
Lunoe, Maren M.
Becker, Sarah M.
Rogers, Alexander J.
Pavlicich, Viviana
Dalziel, Stuart R.
Payne, Daniel C.
Malley, Richard
Borland, Meredith L.
Morrison, Andrea K.
Bhatt, Maala
Rino, Pedro B.
Beneyto Ferre, Isabel
Eckerle, Michelle
Kam, April J.
Chong, Shu-Ling
Palumbo, Laura
Kwok, Maria Y.
Cherry, Jonathan C.
Poonai, Naveen
Waseem, MD; Norma-Jean Simon, MPH
Waseem, Muhammad
Simon, Norma-Jean
Freedman, Stephen B.
Pediatric Emergency Research Network–COVID-19 Study Team
Publication Year :
2022

Abstract

IMPORTANCE Little is known about the risk factors for, and the risk of, developing post-COVID-19 conditions (PCCs) among children. OBJECTIVES To estimate the proportion of SARS-CoV-2-positive children with PCCs 90 days after a positive test result, to compare this proportion with SARS-CoV-2-negative children, and to assess factors associated with PCCs. DESIGN, SETTING, AND PARTICIPANTS This prospective cohort study, conducted in 36 emergency departments (EDs) in 8 countries between March 7, 2020, and January 20, 2021, included 1884 SARS-CoV-2-positive children who completed 90-day follow-up; 1686 of these children were frequency matched by hospitalization status, country, and recruitment date with 1701 SARS-CoV-2-negative controls. EXPOSURE SARS-CoV-2 detected via nucleic acid testing. MAIN OUTCOMES AND MEASURES Post-COVID-19 conditions, defined as any persistent, new, or recurrent health problems reported in the 90-day follow-up survey. RESULTS Of 8642 enrolled children, 2368 (27.4%) were SARS-CoV-2 positive, among whom 2365 (99.9%) had index ED visit disposition data available; among the 1884 children (79.7%) who completed follow-up, the median age was 3 years (IQR, 0-10 years) and 994 (52.8%) were boys. A total of 110 SARS-CoV-2-positive children (5.8%; 95% CI, 4.8%-7.0%) reported PCCs, including 44 of 447 children (9.8%; 95% CI, 7.4%-13.0%) hospitalized during the acute illness and 66 of 1437 children (4.6%; 95% CI, 3.6%-5.8%) not hospitalized during the acute illness (difference. 5.3%; 95% CI, 2.5%-8.5%). Among SARS-CoV-2-positive children, the most common symptom was fatigue or weakness (21 [1.1%]). Characteristics associated with reporting at least 1 PCC at 90 days included being hospitalized 48 hours or more compared with no hospitalization (adjusted odds ratio [aOR], 2.67 [95% CI, 1.63-4.38]); having 4 or more symptoms reported at the index ED visit compared with 1 to 3 symptoms (4-6 symptoms: aOR, 2.35 [95% CI, 1.28-4.31]; >= 7 symptoms: aOR, 4.59 [95% CI

Details

Database :
OAIster
Notes :
This studywas supported by grants from the Canadian Institutes of Health Research (operating grant: COVID-19-clinical management); the Alberta Health Services-University of Calgary-Clinical Research Fund; the Alberta Children's Hospital Research Institute; the COVID-19 Research Accelerator Funding Track (CRAFT) Program at the University of California, Davis; and the Cincinnati Children's Hospital Medical Center Division of Emergency Medicine Small Grants Program. Dr Funk is supported by the University of Calgary Eyes-High PostDoctoral Research Fund. Dr Freedman is supported by the Alberta Children's Hospital Foundation Professorship in Child Health andWellness., English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1346952246
Document Type :
Electronic Resource